SHANE BOXRZ: Open Payments
NPI 1043930894 · LAS VEGAS, NV. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,521 in 38 payments from 10 companies in 2025. Trend: 2023 $432 · 2024 $1,068 · 2025 $1,521
Food & beverage: $1,521
| Company | Payments | Amount |
|---|---|---|
| Amgen Inc. | 8 | $384 |
| ABBVIE INC. | 5 | $350 |
| AstraZeneca Pharmaceuticals LP | 6 | $253 |
| Bayer Healthcare Pharmaceuticals Inc. | 7 | $216 |
| Novo Nordisk Inc | 5 | $145 |
| SANOFI-AVENTIS U.S. LLC | 2 | $68 |
| Exact Sciences Corporation | 2 | $38 |
| PFIZER INC. | 1 | $32 |
| Kowa Pharmaceuticals America, Inc. | 1 | $18 |
| Lilly USA, LLC | 1 | $17 |
Products named: OTEZLA, Kerendia, QULIPTA, UBRELVY, REPATHA, FARXIGA, Ozempic, TZIELD.
Industry payments across NV — which companies pay providers there.
